^PrOPDUALAG^®: A NEW FIXED-DOSE COMBINATION*
OF NIVOLUMAB + RELATLIMAB FOR PATIENTS WITH
UNRESECTABLE OR METASTATIC MELANOMA 

OPDUALAG (nivolumab and relatlimab) demonstrated consistent PFS, OS,

and ORR results vs. nivolumab alone after 3-year of median follow-up^†

CI: confidence interval; HR: hazard ratio; PFS: progression-free survival.

* Clinical significance unknown.

† RELATIVITY-047 is a phase 2/3, randomized, double-blinded trial in 714 patients with previously untreated metastatic or unresectable Stage III or IV melanoma. Patients received OPDUALAG (nivolumab 480 mg and relatlimab 160 mg, n=355) or nivolumab 480 mg (n=359) by IV infusion every 4 weeks until disease progression or unacceptable toxicity. Patients were allowed to have received prior adjuvant or neoadjuvant melanoma therapy: anti-PD-1 therapy, anti-CTLA-4 therapy, or BRAFMEK inhibitors were allowed if there was at least 6 months between the last dose of therapy and date of  recurrence; interferon therapy was allowed if the last dose was at least 6 weeks prior to randomization.

‡ The result of the final OS analysis was not statistically significant.